secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001104659-25-045865
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio Q1 net loss $17.4M; cash $170.6M; trial on track
---------------------------------------------------------

- Net loss $17.4M ($0.19/sh) vs $7.7M ($0.02/sh) in Q1 2024; R&D spend $10.5M (+192% YoY).
- Cash and equivalents $170.6M; runway expected to fund operations through 2027.
- Phase 2 TibuSURE trial for systemic sclerosis continues; HS Phase 2 expected Q2 2025.
- Appointed Kate Dingwall as SVP of Development Operations to support clinical execution.
- G&A expenses $8.8M, increased $4.0M YoY due to compensation and professional fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925045865/0001104659-25-045865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925045865/tm2514121d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer